

April 04, 2016

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Sub: Investor Grievance Redressal Report

Scrip Code: 531099

Pursuant to Regulation 13(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Investor Grievance Redressal Report for the Quarter ended March 31, 2016 is as follows:

DETAILS OF INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	Nil
Received during the quarter	Nil
Disposed of during the quarter	Nil
Remaining unresolved at the end of the quarter	Nil

Please take note of the same.

Thanking you,

Yours faithfully,
For **Rubra Medicaments Limited**



Mayuresh Tawde
Director
DIN – 01999743